Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience

American Journal of Hematology

Volumn 93, Issue 2, 2018, Pages E47-E49

  Slostad, Jessica ^a   Hoversten, Patrick ^a   Haddox, Candace L ^a   Cisak, Kamila ^a   Paludo, Jonas ^a   Tefferi, Ayalew ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZOLE DERIVATIVE; RUXOLITINIB;

CASE REPORT; HEMOPHAGOCYTIC SYNDROME; HUMAN; TREATMENT OUTCOME;

HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; PYRAZOLES; TREATMENT OUTCOME;

EID: 85037350538     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24971     Document Type: Letter

References (6)

1. Esteban YM, de Jong JLO, Tesher MS. An overview of hemophagocytic lymphohistiocytosis. Pediatr Ann. 2017;46(8):e309–e313.
2. Sin J, Zangardi M. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: first case report. Hematol Oncol Stem Cell Ther., in press. [Epub ahead of print].
3. Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017;1(19):1533–1536.
4. Strout MP, Seropian S, Berliner N. Alemtuzumab as a bridge to allogenic SCT in atypical hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol. 2010;7(7):415.
5. Rios-Fernández RL, Callejas-Rubio JL, García-Rodríguez S, Sancho J, Zubiaur M, Ortego-Centeno N. Tocilizumab as an adjuvant therapy for hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis. Am J Ther. 2016;23(5):e1193–e1196.
6. Das R, Guan P, Sprague L, et al. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models or hemophagocytic lymphistiocytosis. Blood. 2016;127(13):1666–1675.